Download Files:
Products Details
Product Description
– Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties[1].
Web ID
– HY-130000
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C27H31ClN4O3
References
– [1]Maehigashi T, et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site. PLoS Pathog. 2021;17(7):e1009671.
CAS Number
– 2245231-10-9
Molecular Weight
– 495.01
SMILES
– O=C([C@H](C1=C(N=C(C2=C1C3=CC=C(C=C3)Cl)N(C(C)=C2C)CC4=CN(N=C4)C)C)OC(C)(C)C)O
Clinical Information
– Phase 2
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– HIV;HIV Integrase
Pathway
– Anti-infection;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
